Products for Research Use Only

Mycophenolate Mofetil

CAT: 0804-HY-B0199-01Size: 100 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0199-01Size:100 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Mycophenolate mofetil (RS 61443) is the morpholinoethylester proagent of Mycophenolic acid. Mycophenolate mofetil inhibits de novo purine synthesis via the inhibition of inosine monophosphate dehydrogenase (IMPDH) . Mycophenolate mofetil shows selective lymphocyte antiproliferative effects involve both T and B cells, preventing antibody formation[1].
CAS Number
128794-94-5
Product Name Alternative
RS 61443; TM-MMF
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Bacterial; Drug Metabolite; Endogenous Metabolite
Type
Reference compound
Related Pathways
Anti-infection; Apoptosis; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/mycophenolate-mofetil.html
Concentration
10mM
Purity
99.83
Solubility
1M NaOH : 33.33 mg/mL (ultrasonic; adjust pH to 12 with 1M NaOH) |DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(OCCN1CCOCC1)CC/C(C)=C/CC2=C(O)C3=C(COC3=O)C(C)=C2OC
Molecular Formula
C23H31NO7
Molecular Weight
433.49
Precautions
H302, H315, H319, H335
References & Citations
[1]Simmons WD, et al. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection. Drug Saf. 1997;17 (2) :75-92.|[2]Fulton B, et al. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs. 1996;51 (2) :278-298.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched

Alternative Products